Miglustat therapy in juvenile Sandhoff disease
- 4 November 2009
- journal article
- case report
- Published by Wiley in Journal of Inherited Metabolic Disease
- Vol. 32 (S1), 289-293
- https://doi.org/10.1007/s10545-009-1224-7
Abstract
GM2-gangliosidosis is a rare and heterogeneous inherited metabolic disorder caused by autosomal recessive mutations in genes encoding the lysosomal enzyme β-hexosaminidase, resulting in the accumulation of ganglioside GM2 in various tissues, particularly the central nervous system. It is characterized by progressive neurological deterioration that mainly affects motor and spinocerebellar function. Several forms of GM2-gangliosidosis exist, including the Sandhoff variant. Currently there is no treatment for these conditions, except for palliative care. Miglustat (Zavesca) is a reversible inhibitor of glucosylceramide synthase, which catalyses the first committed step in the synthesis of glucose-based glycolipids. Miglustat has pharmacokinetic properties that allow it to cross the blood-brain barrier, and preclinical data suggest that it may benefit neuronopathic lysosomal storage diseases. Here we present a case report of a Norwegian patient with Sandhoff disease treated with miglustat at our centre in Norway. The patient initially presented with ataxia and dysarthria at 2–3 years of age, which progressed slowly during childhood. At age 14, he experienced episodes of depression and apathy, leading to weight loss. He was diagnosed with Sandhoff disease at age 16. Following 2.5 years of treatment with miglustat, his body weight was stabilized and disease progression appeared to have slowed, as evidenced by the lack of progressive brain atrophy. His depressive symptoms were managed using electroconvulsive treatment (ECT), which improved general functioning. These findings suggest that miglustat may provide beneficial effects in patients with juvenile Sandhoff disease, and that ECT may alleviate depressive symptoms.Keywords
This publication has 14 references indexed in Scilit:
- Substrate reduction therapy in juvenile GM2 gangliosidosisMolecular Genetics and Metabolism, 2009
- Pharmacokinetics, safety and tolerability of miglustat in the treatment of pediatric patients with GM2 gangliosidosisMolecular Genetics and Metabolism, 2009
- The pharmacokinetics and tissue distribution of the glucosylceramide synthase inhibitor miglustat in the ratXenobiotica, 2007
- The Natural History of Juvenile or Subacute GM2 Gangliosidosis: 21 New Cases and Literature Review of 134 Previously ReportedPublished by American Academy of Pediatrics (AAP) ,2006
- NSAIDs increase survival in the Sandhoff disease mouse: Synergy with N‐butyldeoxynojirimycinAnnals of Neurology, 2004
- Juvenile Sandhoff disease—Nine new cases and a review of the literatureJournal of Inherited Metabolic Disease, 2004
- Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N -butyldeoxynojirimycinProceedings of the National Academy of Sciences, 1999
- The biochemistry of HEXA and HEXB gene mutations causing GM2 gangliosidosisBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1991
- The juvenile and chronic forms of GM 2 gangliosidosisNeurology, 1990
- Thiamin Monophosphate in the CSF of Patients With Amyotrophic Lateral SclerosisArchives of Neurology, 1982